A High Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury during the COVID-19 pandemic뮤신-1 감소 화합물에 대한 고함량 검사를 통해 포스타마티닙이 COVID-19 대유행 기간 동안 급성 폐 손상에 대한 신속한 용도 변경을 위한 후보로 확인됨Article Published on 2020-06-302022-09-11 Journal: bioRxiv [Category] 비임상, [키워드] acute lung injury apical surface approved ARDS arising biochemical marker breath candidate Cell cell surface clinical development clinical outcomes clinical trial clinical trials Compound content COVID-19 pandemic distress drug drug candidate Drug repurposing Efficacy elevated epithelial cells expressed fostamatinib identify Immune thrombocytopenia inhibitor Lung disease lung epithelial cell Lung epithelial cells Lung injury membrane-bound mouse model MUC1 mucin mucosal pandemic pandemic spread Patient patients with COVID-19 predict promoted Protein provide R788 Rapid rationale reduce reduced repurposing required respiratory distress Respiratory distress syndrome reveal SARS-CoV-2 SARS-COV-2 infection Screen spleen Spread Stage standing up SYK syndrome the cell thrombocytopenia Treatment tyrosine [DOI] 10.1101/2020.06.30.180380 PMC 바로가기 [Article Type] Article
Lack of Association Between Genetic Variants at ACE2 and TMPRSS2 Genes Involved in SARS-CoV-2 Infection and Human Quantitative PhenotypesSARS-CoV-2 감염 및 인간의 정량적 표현형에 관여하는 ACE2 및 TMPRSS2 유전자의 유전적 변이체 간의 연관성 부족Genetics Published on 2020-06-082022-08-13 Journal: Frontiers in Genetics [Category] 유전자 메커니즘, [키워드] ACE2 ACE2 gene acute respiratory distress acute respiratory distress syndrome angiotensin angiotensin converting enzyme Angiotensin II Anti-inflammatory ARBs ARBs (angiotensin II receptor blockers) association associations Biomarkers blocker carried cause causes Cell chronic inflammation Cohort combination therapies combination therapy coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient cytokine Cytokines death disease enzyme examined example expression female females flu-like symptoms General population genetic data Genetic predisposition Genetic variant Genetic variation genetics Human human genes hypertension include Infection Invasion male medication medications Mild modulate multifactorial no symptoms NSAIDs (non-steroidal anti-inflammatory drugs) nucleotide outcome phenotype PheWAS Pneumonia priming Quantitative reached receptor Receptor Blockers respiratory distress Respiratory distress syndrome responsible S protein sample sizes SARS-CoV-2 SARS-CoV-2 virus Serine serine protease serine protease TMPRSS2 severe cases severe COVID-19 severity of symptoms significantly Single nucleotide polymorphism single nucleotide polymorphisms SNP SNPs syndrome threshold thrombocyte Thrombocytes thrombocytopenia TMPRSS2 Usage Variability variant Variation virus clearance Volunteer while [DOI] 10.3389/fgene.2020.00613 PMC 바로가기 [Article Type] Genetics
ICU and Ventilator Mortality Among Critically Ill Adults With Coronavirus Disease 2019Article Published on 2020-05-262023-07-02 Journal: Critical Care Medicine [Category] SARS, [키워드] Adult artificial coronavirus Critical care intubation Mortality Respiration Respiratory distress syndrome [DOI] 10.1097/CCM.0000000000004457 PMC 바로가기
Severe COVID-19: A Review of Recent Progress With a Look Toward the Future심각한 COVID-19: 미래를 내다보며 최근 진행 상황 검토Review Published on 2020-05-132022-09-11 Journal: Frontiers in Public Health [Category] MERS, SARS, 치료제, [키워드] acute infectious disease acute respiratory distress acute respiratory distress syndrome acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 alveolar epithelial cells angiotensin Angiotensin-converting enzyme angiotensin-converting enzyme 2 angiotensin-converting enzyme 2 receptors antiviral drug antiviral drugs bind caused clinical manifestations coagulation dysfunction coronavirus coronavirus disease Coronavirus disease 2019 Coronavirus infection COVID-19 cytokine Cytokine storm Diagnosis Epidemiology epithelial cells excessive immune response Future Guidance Health Organization high mortality rate Infection Infectious disease Intensive intensive care intensive care unit lead leads lung tissue injury mechanism Metabolic acidosis Middle East Middle East respiratory syndrome Most patient Most patients multiple organ dysfunction Novel coronavirus novel coronavirus disease organ dysfunction organ function pandemic Pathogenesis Progress protein S recent receptor Respirator respiratory respiratory distress Respiratory distress syndrome review SARS-CoV-2 Septic shock severe acute respiratory syndrome Coronavirus severe cases severe COVID-19 stimulate syndrome systemic inflammatory response the disease toxic effect toxic effects Treatment treatment methods treatment of COVID-19 World Health Organization [DOI] 10.3389/fpubh.2020.00189 PMC 바로가기 [Article Type] Review
Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?세포외 HMGB1: 코로나19를 포함한 중증 폐염증 치료 표적?Review Published on 2020-05-072022-08-13 Journal: Molecular Medicine [Category] MERS, SARS, 유전자 메커니즘, [키워드] 2019 novel coronavirus 2019 novel coronavirus disease activated activated innate immunity cells acute respiratory distress acute respiratory distress syndrome Apoptosis ARDS Blood cause cells from males cellular cytosol complexes concentrations coronavirus disease COVID-19 COVID-19-associated inflammation cytokine cytosolic DAMP DAMPs danger molecule Danger molecules detrimental disease Disulfide Disulfide-HMGB1 dying cell dying cells endocytosed endocytosis endogenous damage-associated molecular pattern endolysosomal system endothelial cells expressed expression Extracellular extracellular DNA Extracellular HMGB1 extracellular SARS-CoV-2 RNA female form HMGB1 identify in vivo individuals induce inflammasome activation Inflammation Influenza initiate innate immunity cells lung Lungs lysosome Lysosomes lytic cell death molecular molecule HMGB1 Necrosis Novel coronavirus novel coronavirus disease observation other molecules PAMP PAMPs pathogen pathogen-associated molecular Pathogenesis pathogenic molecule Pathways physiological plasma Pneumonia pro-inflammatory cytokine pro-inflammatory cytokine release proinflammatory receptor pulmonary endothelial cell pulmonary endothelial cells pulmonary inflammation RAGE reduction released respiratory distress Respiratory distress syndrome RNA SARS-CoV-2 secreted syndrome Therapeutic compounds therapeutic target therapy TLR4 TLR4 receptor TLR4 receptors transfer transported Trigger triggers venous venous blood [DOI] 10.1186/s10020-020-00172-4 PMC 바로가기 [Article Type] Review
Severe acute respiratory distress syndrome in coronavirus disease 2019–infected pregnancy: obstetric and intensive care considerationsArticle Published on 2020-04-142023-06-16 Journal: American journal of obstetrics & gynecology MFM [Category] MERS, SARS, [키워드] acute SARS-CoV-2 ARDS coronavirus COVID-19 Pneumonia Pregnancy Respiratory distress syndrome [DOI] 10.1016/j.ajogmf.2020.100120 PMC 바로가기 [Article Type] Article
Coronavirus disease 2019 (COVID-19) pandemic and pregnancyArticle Published on 2020-03-232023-06-14 Journal: American journal of obstetrics and gynecology [Category] MERS, SARS, [키워드] Antiviral Baricitinib Chloroquine coronavirus COVID-19 Fever Mask MERS-CoV,morbidity Mortality Obstetric management pandemic Pregnancy Remdesivir Respiratory distress syndrome Respiratory failure SARS-CoV SARS-CoV-2 Sepsis susceptibility virus [DOI] 10.1016/j.ajog.2020.03.021 PMC 바로가기
COVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and rationale for a randomized trialDEXamethasone(CoDEX)으로 치료된 COVID-19 관련 ARDS: 무작위 시험에 대한 연구 설계 및 근거Original Article Published on 2020-01-012022-08-13 Journal: Revista Brasileira de Terapia Intensiva [Category] 임상, [키워드] 350 patient 350 patients 48 hour 48 hours 6-level ordinal scale acute respiratory distress acute respiratory distress syndrome acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration Adrenal cortex hormones Adult patients all-cause mortality rate all-cause mortality rates assessment Berlin criteria caused clinical status clinical trial Control control group Controlled trial coronavirus coronavirus disease Coronavirus disease 2019 coronavirus disease 2019 - COVID-19 Corticosteroid Corticosteroides Corticosteroids COVID-19 COVID-19-associated ARDS Cuidados críticos days alive defined develop Dexametasona Dexamethasone dexamethasone 10mg IV dexamethasone 20mg intravenous early-onset Effectiveness Eligible patients evaluate evaluated failure followed by group hospitalized patient hospitalized patients Infection intensive care intervention group intravenous Invasive mechanical ventilation less mechanical ventilation mechanical ventilation duration moderate mortality rates multicenter Non-COVID-19 non-COVID-19 acute respiratory distress syndrome objective occur once daily Open-label Ordinal Scale outcome pandemic Patient patients with moderate Pneumonia Pragmatic Primary outcome randomization Randomized randomized trial Randomly receive respiratory respiratory compromise respiratory distress Respiratory distress syndrome Respiratory distress syndrome, adult Síndrome do desconforto respiratório do adulto SARS-CoV-2 SARS-COV-2 infection score secondary Secondary outcomes severe acute respiratory syndrome Coronavirus Spread standard treatment stratified Study design syndrome treated Trial unit discharge ventilator-free day Ventilator-free days Viral Viral pneumonia [DOI] 10.5935/0103-507X.20200063 PMC 바로가기 [Article Type] Original Article
COVID-19 during pregnancy, delivery and postpartum period based on EBMReview Published on 2020-01-012023-07-05 Journal: Ginekologia polska [Category] SARS, [키워드] coronavirus COVID-19 pandemic Pregnancy Respiratory distress syndrome SARS-CoV-2 [DOI] 10.5603/GP.2020.0106 [Article Type] Review
Use of Intravenous Immunoglobulin (Prevagen or Octagam) for the Treatment of COVID-19: Retrospective Case SeriesCOVID-19 치료를 위한 정맥 면역글로불린(Prevagen 또는 Octagam)의 사용: 후향적 사례 시리즈Observational Study Published on 2020-01-012022-09-11 Journal: Respiration [Category] MERS, 임상, 진단, 치료제, [키워드] acute respiratory distress acute respiratory distress syndrome administration Admission ARDS attenuate caused chronic Clinical course clinical courses clinical trial Comorbidity coronavirus coronavirus disease coronavirus disease 19 COVID-19 COVID-19 infection COVID-19 patient D-dimer demonstrated disease distress dose dose administration doses elevated evaluated hospital discharge Hospital stay ICU Illness severity Immunoglobulin immunomodulators IMPROVE Inflammatory response Inflammatory responses Intravenous immunoglobulin IVIG Mann-Whitney U test mechanical ventilation median median age median time men moderate moderate to severe occurred Patient patients with moderate Physiology ranged reduce reduce mortality regimen resources respiratory distress Respiratory distress syndrome score Sery Severe COVID-19 Infection significantly shorter Stage survived syndrome thrombotic thrombotic event Thrombotic events Treatment utilization Ventilation women [DOI] 10.1159/000511376 PMC 바로가기 [Article Type] Observational Study